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Abstract
Background: Acute pain is among the leading causes of referral 
to the emergency department (ED) in industrialized countries. 
Its management mainly depends on intensity. Moderate-
to-severe pain is treated with intravenous (IV) administered 
opioids, of which morphine is the most commonly used in 
the ED. We have estimated the burden of IV administration 
of morphine in the five key European countries (EU5) using a 
micro-costing approach.
Scope: A structured literature review was conducted to identify 
clinical guidelines for acute pain management in EU5 and 
clinical studies conducted in the ED setting. The data identified 
in this literature review constituted the source for all model 
input parameters, which were clustered as analgesic (morphine), 
material used for IV morphine administration, nurse workforce 
time and management of morphine-related adverse events and 
IV-related complications.
Findings: The cost per patient of IV morphine administration in 
the ED ranges between €18.31 in Spain and €28.38 in Germany. 
If costs associated with the management of morphine-related 
adverse events and IV-related complications are also considered, 
the total costs amount to €121.13–€132.43. The main driver of 
those total costs is the management of IV-related complications 
(phlebitis, extravasation and IV prescription errors; 73% of all 
costs) followed by workforce time (14%).
Conclusions: IV morphine provides effective pain relief in 
the ED, but the costs associated with the IV administration 
inflict an economic burden on the respective national health 
services in EU5. An equally rapid-onset and efficacious 
analgesic that does not require IV administration could reduce 
this burden. 
Keywords: acute pain, analgesia, cost analysis, emergency 
departments, Europe, morphine, nurse, opioids, pain 
management.
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Introduction
Acute pain is one of the leading causes of referral to an 
emergency department (ED), accounting for more than 
two-thirds of these visits [1,2]. Acute pain can be caused by 
a large spectrum of conditions including trauma, renal colic, 
abdominal pain and myocardial infarction, among others. 
Despite all the advances in its diagnosis and treatment, 
management of acute pain in the ED still remains a challenge; 
pain is often under-recognized and undertreated, and in 
busy EDs, initiation of treatment may be delayed [3]. Current 
guidelines recommend analgesia for moderate and severe pain 
to be initiated within 20 minutes of arrival in the ED [3], but this 
is not always feasible. In the French multicenter PALIERS study, 
the time between arrival at the ED and initiation of treatment 
with an analgesic drug was 60 minutes for 38% (379/988) of 
patients with acute pain [4]. 
Intensity of pain (typically defined as mild, moderate or 
severe), along with patient need and initial response to 
analgesia, helps guide its treatment [5]. Although oral 
analgesia is often used to manage pain that is considered mild 
to moderate in severity, moderate-to-severe acute pain may 
frequently be managed with intravenous (IV) administered 
opioids. Although rectal nonsteroidal anti-inflammatory drugs 
are also recommended in a regional guideline in the UK for 
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severe pain [6], per regional guidelines from the UK and Spain, 
IV opioid analgesics remain the mainstay treatment to control 
acute pain in the ED and when needed, they are supplemented 
with oral analgesics [6–10]. The need to administer analgesia 
via the IV route in moderate-to-severe pain can also delay 
initiation of pain relief, particularly in patients with difficult 
IV access. Although placement of an IV catheter by a nurse is 
successfully achieved for the majority of patients, in certain 
cases such as obesity, elderly patients or vasoconstriction 
brought on by shock, cannulation may need to be conducted 
with the assistance of ultrasonographic guidance, which 
substantially delays IV access. Placement of an IV catheter – 
which, by its nature, is more time-consuming and complex 
[11] compared with administration of, for example, orally 
administered drugs – in these patients may take between  
30 minutes and 2 hours [12]. 
Nurse-administered IV morphine is the most commonly used 
analgesic method for moderate-to-severe pain in the ED 
in the five key European countries (EU5 [France, Germany, 
Italy, Spain and the UK]). However, fewer than a handful of 
studies have assessed the costs associated with this modality 
of administering analgesia in the ED setting. The studies 
conducted to date had either a US [13,14] or Hong Kong [15] 
perspective; none had a European focus. The aim of this study 
was to measure the costs associated with nurse-administered IV 
morphine for the management of acute pain in the ED setting 
in EU5. Costs were estimated for each of these countries using a 
micro-costing analysis. 
Methods
Costs of IV morphine administration in the ED are not readily 
available from any public database. Therefore, a structured 
literature review was conducted to identify all the data 
needed for the micro-costing analysis. The literature review 
aimed to identify clinical guidelines for the management of 
moderate-to-severe acute pain in the ED setting in the EU5 
and providing a comprehensive list of the interventional and 
observational ED studies on acute pain. All searches were 
performed in PubMed and Google, and included the following 
concepts: ‘acute pain’, ‘intravenous morphine’ and ‘emergency 
department or room’. Google searches additionally included 
use of local languages (e.g. ‘guía práctica del manejo del dolor 
en urgencias’ [Spain] and ‘prise en charge de la douleur aux 
urgencies’ [France]).
At the time our search was conducted (2016), we were able to 
identify six regional and two national European guidelines. 
Regional guidelines included four from the UK [6,8–10], one  
from Spain [7] and one from France [16]. National guidelines 
included one from Spain [17] and one from Italy [18]. The 
interventional and observational studies that were identified 
represented a cross-section of European and other countries, 
including four of the five EU5 countries (France, Italy, Spain and 
the UK) (Table 1).
The model developed in Microsoft Excel estimated the costs 
associated with the management of an average patient with 
moderate-to-severe acute pain of any origin with nurse-
administered IV morphine in the ED from a national health 
service perspective. The input categories were as follows: 
analgesic administered IV, workforce time spent on IV 
morphine administration and monitoring the patient, material 
needed for the IV administration, adverse events reported 
during administration of IV morphine and complications of IV 
administration (Table 1). Unit prices and costs included in the 
model were country-specific and adjusted to 2016 euros  
(Table 2). The only exception was costs for management of 
respiratory depression [54] and of IV prescription errors [55], 
which were derived from US costs because no data were 
identified in the literature review for Europe.
Based on seven ED studies (914 patients) [19–25] and in 
line with recommendations from the regional and national 
European guidelines [6–10,16–18], patients received up to  
10 mg of morphine in the model (Table 1). The cost of  
morphine included in the model was its ex-VAT public selling 
price in 2016 in EU5. The model considers that morphine is 
administered as four doses as part of a typical dose-titration 
procedure [6–10,16–18]. IV morphine is prepared by the  
dilution of 1 mL morphine (10 mg/mL) with 9 mL saline (0.9%), 
in a syringe. 
Regarding workforce (i.e. nurses), the time needed to 
administer IV morphine was estimated based on the regional 
clinical guidelines from the UK [6,8–10], Spain [7] and ED studies 
[12,15,19,26–28,32–35] identified in the structured literature 
review. The inputs that constituted the cost of workforce in 
the micro-costing model were the costs of nursing time for 
the following procedures: cannulation, drug preparation, drug 
administration, patient monitoring and flushing of the IV line 
(Figure 1). The per-minute cost of nurse time was calculated 
from available annual, monthly or hourly salaries based on  
the assumption that 40 hours per week were worked for  
47 weeks per calendar year. Salaries were adjusted to 2016 
using each country’s consumer price index (Table 1). We assume 
that nurses spend an average of 4.1 minutes per IV cannulation 
attempt, based on four ED studies (1011 subjects) [12,26–28]. 
Also based on ED studies (n=3414 patients) [12,26–31], we 
assume that each patient has 1.3 IV attempts. Nurses spend 
7.9 minutes for drug preparation based on two studies that 
assessed the average time required to prepare a solution for 
IV injection via a syringe [15,32]. The amount of time spent by 
a nurse on drug administration (i.e. 3.7 minutes) was derived 
from four studies (720 subjects) that monitored the amount 
of time needed to administer a single IV bolus of morphine in 
the ED [15,19,34–35]. This time is in line with the 4 to 5 minutes 
recommended in the label of morphine [56]. None of the 
identified clinical studies detailed the time needed for patient 
monitoring, therefore, assumptions based on regional clinical 
guidelines from the UK [6,8–10] and Spain [7] were made. 
According to these guidelines, patients’ vital signs (including 
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Table 1. Summary of noncosts input parameters.
Costing input Input 
parameter
# Studies Sample size Reference source (region)
Practice guidelines
R=regional
N=national
Clinical studies
Drug
Morphine 10-mg dose 7 914 [6,8–10] (UK–R)
[7] (Spain–R)
[17] (Spain–N)
[16] (France–R)
[18] (Italy–N)
[19–21] (US)
[22] (UK)
[23] (France)
[24] (New Zealand)
[25] (Malaysia)
Materials
IV cannula infusion set 1.3 units 7 3414 [12,26] (US)
[27–29] (France)
[30] (Australia)
[31] (Spain) 
Draw-up needles 2 units - - [6,8–10] (UK–R)
[7] (Spain–R)
[17] (Spain–N)
[16] (France–R)
[18] (Italy–N)
Syringe (10 mL) 1 unit - - [6,8–10] (UK–R)
[7] (Spain–R)
[17] (Spain–N)
[16] (France–R)
[18] (Italy–N)
Saline (100 mL) for dilution 1 unit - - [6,8–10] (UK–R)
[7] (Spain–R)
[17] (Spain–N)
[16] (France–R)
[18] (Italy–N)
Prefilled (10 mL) saline syringe 1 unit - - [6,8–10] (UK–R)
[7] (Spain–R)
[17] (Spain–N)
[16] (France–R)
[18] (Italy–N)
Workforce
Cannulation 5.4 mins 4 1011 [12,26] (US)
[27,28] (France)
Drug preparation 7.9 mins 2 121 [15] (Hong Kong)
[32] (UK)
Flushing 2.0 mins 1 35 [33] (Australia)
Drug administration 14.8 mins 4 720 [15] (Hong Kong)
[19,34,35] (US)
Patient monitoring 14.0 mins - - [6,8–10] (UK–R)
[7] (Spain–R)
Management of adverse events (rate)
Nausea 12.1% 14 1443 [19–21,34–38] (US)
[22] (UK)
[39–41] (Iran)
[42] (France)
[43] (Belgium)
(Continued)
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heart rate, blood pressure, oxygen saturation and respiratory 
rate) and pain relief should be monitored before, during and 
after morphine administration. We estimated that a nurse 
would spend 2 minutes checking a patient’s vital signs and/
or pain levels. As shown in Figure 1, the time spent monitoring 
would be 2 minutes prior to the first morphine dose, an 
additional 2 minutes before each dose during dose titration 
and 2 minutes every 5 minutes over a 22-minute period after 
the last morphine dose. The average amount of time spent by 
a nurse on IV flushing was derived from one Australian study 
[33] that assessed the time required by nurses to prepare and 
administer prefilled saline flush solutions to 35 patients in a 
laboratory setting; an average of 2 minutes was reported. We 
consider that flushing is performed only once, before the first 
dose of morphine is administered and that the nurse needs  
2 minutes. When considering all the steps where nurses  
time themselves, the total nurse time needed for each IV 
morphine administration including time to monitor the  
patient is 44 minutes.
The inputs that constituted the cost of materials in the 
micro-costing model were for the following items: a cannula 
infusion set, draw-up needles, a syringe, saline and a prefilled 
saline flush syringe. For each of these materials, costs taken 
were based on prices paid by EU5 hospitals. Where this was 
not possible, prices were obtained from medical equipment 
suppliers, which is one of the limitations of our analysis.  
A cannula infusion set was assumed to be required per attempt. 
Therefore, a total of 1.3 cannulation sets was required per 
patient. In addition, two draw-up needles (one for saline and 
one for morphine) and a single 10 mL syringe were required 
to prepare the morphine solution per patient. To prepare the 
solution, one 100 mL bag of saline (the smallest common pack 
size in countries within scope) was estimated per patient; 
consequently, this cost includes wastage for saline. In contrast, 
a prefilled saline flush syringe was used for flushing.
The micro-costing model also included the cost of 
management of key adverse events associated with  
Table 1. (Continued)
Costing input Input 
parameter
# Studies Sample size Reference source (region)
Practice guidelines
R=regional
N=national
Clinical studies
Vomiting 5.8% 11 906 [19,21,34,35,37,38] 
(US)
[22] (UK)
[42] (France)
[40,44] (Iran)
[43] (Belgium)
Hypotension 2.1% 8 1154 [20,37,38] (US)
[42] (France)
[40,44] (Iran)
[45] (Australia)
[46,47] (Turkey)
Respiratory depression 1.1% 9 1710 [22] (UK)
[20,38] (US)
[23,41] (France)
[24] (New Zealand)
[45] (Australia)
[46,47] (Turkey)
IV complication treatment (rate)
Phlebitis 2.6% 1 1498 [48] (Italy)
Extravasation 0.4% 4 102,204 [49,50] (US)
[51] (Brazil)
[52] (Japan)
Harmful IV prescribing errors 1.2% 1 330 [53] (UK)
The data for each input parameter as well as the sources of these data are provided in the table above. The column titled  
# studies provides the number of studies used as the source of the input parameter. The column titled sample size provides the 
total number of patients included in the source studies.
IV, intravenous; mins, minutes; UK, United Kingdom; US, United States.
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Table 2. Summary of costs data inputs.
Costs per unit in 2016 euros
FR DE IT ES UK
Drug 
Morphine (10 mg) 0.88 1.56 0.63 0.30 1.20
Material 
Cannula infusion seta 0.21 1.13 0.41 1.36 0.85
Draw-up needlea 0.12 0.08 0.05 0.04 0.07
Syringea 0.29 0.24 0.03 0.08 0.04
Saline for dilutiona 3.12 2.76 2.00 1.56 1.49
Prefilled saline syringe for line flushinga 0.80 1.07 0.67 0.28 0.43
Workforce
Cost per minute of nurse time 0.46 0.49 0.48 0.32 0.25
Adverse events
Nauseab 9.41 11.76 9.24 6.11 5.13
Vomitingb 17.09 19.81 17.22 11.45 9.23
Hypotensionb 5.00 5.17 6.22 3.85 3.66
Respiratory depressionb,c 796 796 796 796 796
IV complications
Phlebitisb 2.79 4.14 3.15 3.54 2.48
IV prescription errorsb,c 7622 7622 7622 7622 7622
Extravasationb 2.79 4.14 3.15 3.54 2.48
Costs are given as 2016 euros adjusted costs. aCosts are given per unit. bCosts are given per episode. cThese costs were derived 
from US sources unlike all other costs which were country-specific. 
DE, Germany; ES, Spain; FR, France; IT, Italy; IV, intravenous; UK, United Kingdom.
IV administration of morphine. The adverse events included in 
the model were nausea, vomiting, hypotension and respiratory 
depression. Probability of experiencing any of these events  
was derived from ED studies where a comparable IV morphine 
dose was administered also in the ED. As shown in Table 1,  
the probability of nausea was derived from 14 studies (1443 
patients) [19–22,34–43], vomiting from 11 studies (906 patients) 
[19,21,22,34,35,37,38,40,42–44], hypotension from nine  
studies (1154 patients) [20,37,38,40,42,44–47] and severe 
respiratory depression from nine studies (1710 patients)  
[20,22–24,38,41,45–47]. These probabilities were 0.121, 0.058, 
0.021 and 0.011, respectively. Onset of nausea and/or vomiting 
was treated with antiemetic therapy. For simplicity, all patients 
with nausea or vomiting received metoclopramide in our 
model. Based on its label [57], 10 mg (one 2 mL ampoule of  
5 mg/mL) of metoclopramide was given IV. This administration 
required two draw-up needles (one for metoclopramide and 
one for saline), one 10 mL syringe and one prefilled saline 
flush syringe. No additional costs were included for the saline 
needed for preparing the metoclopramide solution, as it is 
assumed that saline is taken from the 100 mL bag used for 
preparing the morphine solution. Nursing time associated  
with the treatment of IV-morphine induced nausea and 
vomiting was derived from Eberhart et al. [58], a German study 
(149 subjects) that measured the time spent by nurses to  
treat episodes of nausea and/or vomiting in a general ward. 
Time for management of nausea and vomiting was 16.9 and  
33.4 minutes, respectively. Management of hypotension 
consisted of administering saline [20]. The cost of one 1000 mL 
saline bag for infusion was included in the model. We assumed 
that the saline administration required 5.4 minutes from a 
nurse [59]. Finally, the cost of management of severe respiratory 
depression was derived from Kane-Gill et al. [54]. 
Complications associated with IV administration of drugs were 
also included in our model. The inputs that constituted the cost 
of IV-related complications in the micro-costing model were 
the costs associated with the risk of developing the following 
complications due to IV administration: phlebitis, extravasation 
and the harmful events following IV prescribing errors. No 
studies that assessed the incidence of phlebitis in the ED 
were identified. In lieu of this data, the incidence of phlebitis 
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was derived from one clinical study (1498 subjects) [48] 
where the occurrence of phlebitis within 24 hours of catheter 
insertion was monitored across medical and surgical wards 
(the emergency room was not considered as a ‘location’) in an 
Italian hospital. Based on this study, the probability of phlebitis 
was set as 0.026 in the model. Probability of extravasation  
after morphine administration was derived from four 
clinical studies (102,204 subjects) [49–52] that assessed 
extravasation after the administration of either IV contrast or 
chemotherapeutics. The probability was 0.004. Probability 
of IV morphine prescribing errors is based on the findings of 
Davies et al. [53], which examined prescription errors across 
type of opioid and route of administration. The authors report 
an incidence of 1.2% for potentially lethal prescribing errors. 
In the model, we assume that management of phlebitis and 
extravasation consists of inserting a new IV catheter. The costs 
associated with phlebitis and extravasation included both the 
materials and workforce costs of inserting a new IV catheter. 
The cost of treating harmful medication errors was derived 
from Abraham et al. [55]. 
The materials used during management of adverse events 
or IV complications are not included in the costs of materials, 
as they are already included in the costs of management of 
adverse events. Similarly, costs of nurse time dedicated in 
the management of adverse events and IV complications are 
considered in the costs of adverse events and IV complications, 
respectively, and not in the costs of workforce time.
Results
As shown in Table 3 and Figure 2, the costs for all model  
input parameters were comparable across the EU5 countries. 
The costs of IV administration of morphine ranged from  
€18.31 per patient in Spain to €28.38 per patient in Germany. 
Of these costs, those associated with the time nurses spend to 
administer the morphine and monitor patients during and after 
morphine administration are the highest (between €14 [€14.03 
in the UK and €14.29 in Spain] and €21–€22 [€21.35 in Italy and 
€21.52 in Germany]). In terms of workforce costs, the prominent 
ones were the costs associated with drug administration 
(€4.71 per patient in the UK to €7.23 per patient in Germany) 
and monitoring of the patient (€4.45 per patient in the UK to 
€6.83 per patient in Germany). The costs of morphine were the 
lowest ones in all countries with a cost ranging between €0.30 
per patient in Spain and €1.56 per patient in Germany. Costs of 
material ranged between €3.16 in Italy and €5.30 in Germany 
(per patient). 
When we include the contribution of costs associated with 
management of adverse events and of IV complications, 
the total costs associated with morphine IV administration 
Figure 1. Procedure of IV morphine administration in the ED setting.
All time values in the figure correspond to those required per patient. Example, it was assumed that time for 
cannulation is 4.1 minutes, but given that patients would have an average of 1.3 attempts, the total time for cannulation 
is 5.4 minutes per patient.
ED, emergency department; IV, intravenous; mins, minutes.
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Table 3. Average cost per patient.
Costing input Cost in 2016 euros
FR DE IT ES UK
Drug          
Morphine 0.88 1.56 0.63 0.30 1.20
Materials          
IV cannula infusion set 0.28 1.51 0.55 1.79 1.46
Draw-up needles 0.25 0.16 0.10 0.07 0.17
Syringe (10 mL) 0.29 0.24 0.03 0.08 0.06
Saline (100 mL) for dilution 3.06 2.32 1.81 1.50 1.91
Prefilled (10 mL) saline syringe 0.80 1.07 0.67 0.27 0.56
Workforce          
Cannulation 2.51 2.63 2.61 1.75 1.71 
Drug preparation 3.68 3.85 3.82 2.56 2.51 
Flushing 0.93 0.98 0.97 0.65 0.64 
Drug administration 6.90 7.23 7.17 4.80 4.71 
Patient monitoring 6.52 6.83 6.78 4.54 4.45 
Management of adverse events          
Nausea 1.13 1.42 1.11 0.74 0.79
Vomiting 1.00 1.16 1.01 0.67 0.69
Hypotension 0.10 0.11 0.13 0.08 0.10
Respiratory depression 8.84 8.84 8.84 8.84 8.84
IV complications treatment          
Phlebitis 0.07 0.11 0.08 0.09 0.08
Extravasation 0.01 0.02 0.01 0.01 0.01
Harmful IV prescribing errors 92.39 92.39 92.39 92.39 92.39
Aggregated costs
Drug administrationa 26.09 28.38 25.14 18.31 19.37
Adverse events and IV complications 103.56 104.04 103.58 102.83 102.91
Total 129.64 132.43 128.72 121.13 122.28
aDrug administration costs include the costs of drug, material and workforce and exclude any costs due to management of 
adverse events or IV-related complications. 
DE, Germany; ES, Spain; FR, France; IT, Italy; IV, intravenous; UK, United Kingdom.
for moderate-to-severe acute pain in the ED setting ranged 
between €121.13 per patient in Spain to €132.43 per patient in 
Germany. Costs of management of IV complications were the 
main driver of our model and account for 73% of the total costs 
(Figure 3). Regarding these costs, the prominent component 
was the costs of IV prescription errors (€92.39 per patient).  
Costs of phlebitis (€0.07– €0.11 per patient) and extravasation 
(€0.01– €0.02 per patient) were only marginal. 
The total costs associated with the management of key adverse 
events of IV morphine, including phlebitis, injection site pain 
and infections associated with IV administration, ranged 
between €10.33 per patient in Spain to €11.53 per patient in 
Germany. The adverse event associated with highest costs 
was severe respiratory depression (€8.84 per patient). Costs 
of nausea and vomiting were significantly lower than those of 
respiratory depression and primarily driven by the time nurses 
spend to manage these patients.
Discussion
The current micro-costing analysis highlights the economic 
burden inflicted by administration of IV morphine for 
moderate-to-severe acute pain in the ED setting in the EU5 
countries. The cost of IV morphine administration for acute 
pain in the ED ranged between €18 and €28 per patient in the 
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nausea, vomiting and phlebitis as adverse events of interest, 
but they also estimated the economic impact of treating 
drowsiness, sleeping and dizziness in their model [15]. The 
mean costs per person when excluding subsequent hospital 
admission was $HK228.80 (€37.13, 2016 values) for patients  
who received nurse-titrated IV morphine. These costs were 
$HK43.60 (€7.08, 2016 values) for patients randomized to IV 
ketorolac. The average total costs estimated by Rainer et al. 
were lower than ours due to Rainer et al. not considering the 
cost of the material used for IV administration and importantly, 
failing to include the contribution of respiratory depression 
and IV prescription errors [15]. Total costs estimated by Rainer 
et al. were lower than ours, despite a higher incidence of 
patients with nausea, vomiting and phlebitis in Rainer et al. Of 
these adverse events, incidence of phlebitis after IV morphine 
administration was particularly high in Rainer et al. (27 vs 2.6% 
in our model).
The second study providing costs for IV morphine was 
commissioned by Medical Developments International 
Limited and aimed at comparing the costs of using Penthrox 
(methoxyflurane given through an inhaler) to those of IV 
morphine for the treatment of acute pain in the ED [13].  
Costs associated with IV morphine amounted to US$33.18 
(2008 values; €23.80 when inflated to 2016 values). Costs were 
estimated based on published literature and primary interviews 
with ED staff. The input parameters in their model included 
costs of analgesia, material, workforce time and management 
of two adverse events (nausea and vomiting). These costs were 
similar to ours when we excluded costs of respiratory depression 
and IV prescription errors. However, costs estimated by Medical 
Developments International Limited [13] were significantly  
lower than those currently estimated by Palmer et al. [14].  
EU5 when considering the costs of the analgesic, material and 
workforce (which includes nursing time, training and effort). 
These costs amount to between €121 and €132 per patient 
when also including the contribution of management of 
adverse events and IV complications. 
Although acute pain is one of the leading causes of referral 
to ED, very few studies have assessed the economic burden 
of its management in this setting, with only three of these 
studies focusing on nurse-administered IV analgesia [13–15]. 
The approach and input parameters estimated in these three 
studies differ from ours and also among themselves. The first 
study compares the costs of nurse-administered IV ketorolac 
and IV morphine in the ED [15]. The study conducted in the ED 
of a large hospital in Hong Kong included the costs of drugs, 
nurse workforce time and adverse events collected in their 
hospital [15]. Similar to our analysis, Rainer et al. considered 
Figure 2. Average costs per patient and country.
IV, intravenous.
Figure 3.  Contribution of the different model 
components.
IV, intravenous. 
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errors to the prescription ones (e.g. inappropriate opioid) and 
excluded any dosing errors from nurses. No European-specific 
data were identified in the literature review regarding the  
costs of prescription errors for morphine or other types of 
opioids. Only US costs were identified and these are the ones 
applied to our analysis. Although the most costly component 
was IV infusion pumps, which are more commonly used in 
United States than in Europe, they do represent possible costs 
in Europe, as EDs become more specialized [61]. These costs 
were taken from the poster presented by Abraham et al.  
at the 20th annual meeting of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) [55]. The 
authors provide only limited information regarding how these 
costs were derived from the original estimated by Meissner 
et al. [62]. Meissner et al. estimated the costs associated with 
the management of the consequences of different types of  
errors based on clinical assumptions validated by an expert 
advisory panel. 
We also included two additional types of IV-related 
complications: extravasation and phlebitis. The costs 
associated with their management were significantly lower 
than the costs of IV prescription errors. Morphine is not an 
irritant drug and therefore, extravasation does not cause 
any tissue damage [63]. When extravasation occurs, the 
only action needed is to place a new IV catheter. Regarding 
phlebitis, we took a conservative approach and assumed that 
all cases of phlebitis were uncomplicated and therefore, would 
only require placement of a new IV line. Unlike Rainer et al. 
[15], who considered phlebitis an adverse event, we included 
it as an IV-related complication. As already mentioned, 
in Rainer et al., the incidence of phlebitis was particularly 
high (27 vs 2.6% in our model) for the ED setting [15]. We 
have considered that the reported incidence for phlebitis in 
Rainer et al. is too high to reflect current clinical practice and 
therefore, this study was not included in the calculation of the 
incidence of phlebitis.
Limitations of the study
Similar to other economic models, our analysis has a number of 
limitations. The analysis we have conducted was restricted to 
morphine only. Although morphine is still the most commonly 
used opioid for management of moderate-to-severe acute pain 
in the ED in EU5, more potent opioids such as hydromorphone 
and fentanyl are gaining popularity [64]. However, these 
opioids are more expensive than morphine; therefore, the real 
economic burden of the use of IV opioids as analgesics for 
acute pain is likely to exceed our estimates. Similarly, we also 
took a conservative approach by assuming that all patients  
with an episode of nausea and/or vomiting receive 10 mg  
of IV metoclopramide rather than more costly antiemetics  
(e.g. ondansetron), which are also used for opioid-related 
nausea and vomiting [65]. In contrast, the rebate applied to 
hospitals for material was not available for all materials and 
for all countries. When unavailable, we used the costs from 
In the model by Palmer et al., the cost of the IV infusion pump 
(US$37±29; €33.59±26.33; 2016 values) was included, and 
this was the most costly component [14]. However, the use 
of infusion pumps is not included in regional and national 
European clinical guidelines and thus this additional cost 
burden may likely not be incurred by countries in Europe. In 
our own personal communications with ED staff from the EU5 
countries, infusion pumps, unlike in the United States, are not 
readily used in the ED for administering IV morphine in Europe. 
The adverse events included in our analysis differ from those 
considered in the other economic studies. To simplify our 
model, we restricted the adverse events to nausea, vomiting, 
hypotension and respiratory depression. It can be argued 
that the latter is more uncommon than the other three. The 
ED studies identified in the literature showed an incidence 
of 12.1% for nausea, 5.8% for vomiting, 2.1% for hypotension 
and 1.1% for respiratory depression. However, despite its low 
incidence, respiratory depression is one of the most serious 
adverse events associated with the use of IV morphine and 
can have devastating outcomes. In line with the clinical 
relevance of this adverse event, the costs associated with 
its management, such as nursing costs, monitoring of vital 
signs and monitoring of oxygen saturation, were the highest 
among all the modeled adverse events. The other three 
adverse events were associated with only marginal costs, 
particularly, hypotension. In our model, we estimate that the 
cost of treating an episode of nausea would range between 
€5 and €12 in the EU5 and between €9 and €20 for an episode 
of vomiting. These costs are lower than those estimated by 
Eberhart et al. in Germany [58]. The authors estimated the cost 
of an episode of nausea and/or vomiting that occurred during 
or after administration of opioid drug, based on the data from 
462 inpatients in 16 German hospitals. The costs for an episode 
of nausea and/or vomiting was estimated as €31±22 when 
including both the workforce time (€18±14) and materials 
(€14±13) [58]. The higher costs in Eberhart et al., compared with 
our estimates, are partly due to inclusion in Eberhart et al. of 
the costs of material, such as IV lines or gastric tubes, that had 
to be replaced because of nausea and/or vomiting. These costs 
were not included in our model.
The main driver of our model was the cost of IV-related 
complications. Of these, the cost of IV prescription errors had 
the highest contribution to the total costs. According to the 
Institute for Safe Medication Practices, opioids are considered 
to be high-risk medications and medication errors associated 
with opioids can have serious consequences [60]. Prescription 
errors are common in hospitals and in the case of opioids, 
these errors are particularly likely, given the wide variety of 
drugs, preparations and doses available. The incidence we have 
modeled for these errors is based on the findings of Davies 
et al. based on the review of inpatient drug charts in a large 
UK University teaching hospital [53]. In our model we took a 
conservative approach and only considered life-threatening 
errors. In line with this conservative approach, we limited the 
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suppliers, which may have overestimated these costs. While 
this is a limitation, it has only a marginal impact, given that 
material-related costs accounted for less than 5% of the 
total costs.
While this model did include workforce costs, it is possible 
these costs were underestimated. Setting up an IV and 
administering and monitoring opioids may lead to a delay  
in care for other patients. Delays in patient treatment can 
lead to increases in patient stay, overcrowding in the ED, 
increases in adverse events and an overall increase in cost 
[66]. Therefore, there may be additional tangential costs in  
IV morphine administration that were not accounted for in 
this model. 
The model was simplified by assuming all patients reach pain 
relief with a dose of morphine equal or lower than 10 mg. In 
clinical practice, patients often receive supportive treatment 
with oral analgesics and in a considerable percentage of 
patients, doses higher than 10 mg of morphine are needed 
[6–10,16–18]. An additional limitation of our model is the 
reduced number of adverse events (n=4) and IV-related 
complications (n=3) included in the analysis. The model does 
not reflect the contribution of other adverse events, such as 
sedation or pruritus, or IV-related complications, such as needle 
stick injuries. Their inclusion would have equally increased the 
costs of IV-administered morphine.
Lack of real-world costs for IV administration of morphine in the 
ED setting in the countries of interest prompted us to conduct 
a structured literature review to identify all the data needed 
to calculate these costs. In order to simulate clinical practice in 
these countries as closely as possible, we prioritized data from 
observational studies conducted in the ED setting (including in 
the UK and in France) and the available regional and/or national 
clinical guidelines in the UK, Spain, Italy and France for the dose 
of opioids administered in the ED and workforce time. One real 
but often overlooked cost not included in our model is the time 
it takes nurses to waste unused morphine. In many institutions, 
nurses must also take the time to find a second healthcare 
provider to witness and cosign the proper destruction of the 
opioid, which likely adds several more minutes for parenteral 
administration. In addition, all data related to adverse events 
for IV morphine originated from ED studies where the dose 
of administered morphine was comparable to that used in 
our model and related to short exposure to morphine in the 
ED setting. All costs used in the model were country-specific 
and inflation adjusted, when needed, to 2016 using each 
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country’s consumer price index. As previously mentioned, there 
were two exceptions (costs for management of respiratory 
depression and of opioid prescription errors) because no data 
were identified in the literature review for the ED in Europe. The 
costs of respiratory depression were derived from US costs and 
the modeled rate of prescription errors originates from a single 
study conducted in a UK University teaching hospital. The 
authors report rates of prescription errors in wards rather than 
in the ED [53]. Therefore, this study may not be representative 
of all EU5 countries. Further, this study did not compare routes 
of administration; however, a study by Beaudoin et al. showed 
that the IV administration of opioids in the ED resulted in more 
medical errors (and harm due to medical errors) than did oral 
administration [67]. As previously mentioned, the costs for 
prescription errors in the current study come from a US study 
[55]. It can be argued that US costs are higher than European 
costs; however, this was offset by excluding nonharmful 
events from our analysis. Given these limitations, the costs of 
prescription errors should be taken with caution.
Our model measures the average cost in the EU5. Although we 
prioritized inclusion of published data specific for the ED setting, 
these data may not take into account variability within and across 
countries. However, our model provides the cost ranges based 
on European regional and national guidelines [6–10,16–18], as 
well as studies from four of the five EU5 (France [23,27,28,41,42], 
Spain [31], the UK [22,53], Italy [48]) and other countries. Costs 
of administering IV morphine in the ED are likely to be between 
€10.90–€17.50 (for those patients who are easily cannulated and 
for whom vitals are not affected) and €18.30–€28.40 (for those 
patients with difficult IV access and with underlying conditions 
that may require additional monitoring).
Conclusion
Our model is a simplified representation of actual clinical 
practice; it informs on the economic burden, including the 
time and effort required, of nurse-administered IV analgesia 
with morphine in the ED setting. Nurse time spent on IV 
administration is the second most important driver in our 
model after the costs of IV-related complications, even  
when we use the lowest reported workforce time values.  
The use of an equally rapid-onset and efficacious analgesic 
that can be administered using a less burdensome route  
(e.g. oral, sublingual or inhaled) may reduce the costs of  
analgesia for moderate-to-severe acute pain in the ED 
setting.
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